The use of botulinum toxin in Raynaud phenomenon: a comprehensive literature review

O Lawson, A Sisti, P Konofaos - Annals of plastic surgery, 2023 - journals.lww.com
Background Raynaud phenomenon (RP) is a vasospastic condition of the digits that can be
primary or secondary to systemic disease. Symptoms are triggered by cold or stress and can …

The efficacy of botulinum toxin a in the treatment of Raynaud's phenomenon in systemic sclerosis: a randomized self‐controlled trial

W Du, M Zhou, C Zhang, Q Sun - Dermatologic Therapy, 2022 - Wiley Online Library
The current conservative and surgical treatments are not fully effective and have
complications for Raynaud's phenomenon (RP) secondary to systemic sclerosis (SSc) …

Botulinum toxin type A in the treatment of Raynaud's phenomenon

SM Habib, EEA Brenninkmeijer… - Dermatologic …, 2020 - Wiley Online Library
Raynaud's phenomenon is a vasospastic disorder clinically characterized by cold or stress‐
induced discoloration of the skin, pain and ulcers of the fingers or toes. Although this …

[HTML][HTML] OnabotulinumtoxinA improves oral aperture in patients with scleroderma: a small clinical trial

CD Gonzalez, JJ Pamatmat, KM Burningham… - Journal of the American …, 2023 - Elsevier
Background Reduced oral aperture (ROA) resulting from systemic sclerosis (SSc) is a
debilitating condition with limited treatment options. Improvement in oral function has been …

BTX-A promotes expression of angiogenesis-associated genes in human umbilical vein endothelial cells

X Wu, Y Zhang, L Chen, Y Han, Y Song… - DNA and Cell …, 2020 - liebertpub.com
Raynaud's phenomenon (RP) is an episodic vasospasm of the peripheral arteries caused by
an exaggerated reaction to cold temperature or emotional stress. Restoring the …

Estudio retrospectivo sobre la efectividad de la infiltración ecoguiada interdigital de toxina botulínica para el tratamiento del fenómeno de Raynaud

ÁEP Ezaine, MAR Huaranga, RA López… - Revista Colombiana de …, 2024 - Elsevier
Introducción El fenómeno de Raynaud (FR) es una condición vasoespástica que conlleva
una carga significativa de dolor y discapacidad. Cuando las terapias habituales no son …

Use of botulinum toxin type A in rheumatic diseases

ON Egorova, BS Belov, EG Sazhina - Modern Rheumatology …, 2021 - mrj.ima-press.net
The article presents an analysis of modern data on the antinociceptive effectiveness of
botulinum toxin type A (BTA) in rheumatic diseases (RD). The prospects for the use of BTA in …

[HTML][HTML] Применение ботулинического токсина типа A при ревматических заболеваниях

ОН Егорова, БС Белов, ЕГ Сажина - Современная ревматология, 2021 - cyberleninka.ru
В статье представлен анализ современных данных об эффективности
антиноцицептивного действия ботулинического токсина типа А (БТА) при …